Literature DB >> 10037311

Hyperparathyroidism and pregnancy.

K C Kort1, H J Schiller, P J Numann.   

Abstract

BACKGROUND: Hyperparathyroidism during pregnancy can carry significant morbidity to both mother and fetus. Surgery is the definitive treatment of choice although medical management is occasionally warranted. This report looks at 6 cases of hyperparathyroidism during pregnancy and reviews the morbidity and mortality of this entity.
METHODS: We retrospectively reviewed all parathyroidectomies performed over a 21-year period (May 1975 to May 1996). A total of 750 cases were performed. In 6 cases, hyperparathyroidism occurred during pregnancy. Serum calcium was measured in all patients before and after parathyroidectomy.
RESULTS: A total of 6 of 750 patients (0.8%) were found to have hyperparathyroidism during pregnancy. In this review, fetal mortality rate was 17% (1 of 6). Two infants experienced neonatal tetany. Maternal morbidity included 1 woman who developed hypercalcemic crisis and acute pancreatitis. Two patients presented with hyperemesis gravidarum, 2 were asymptomatic, and 1 had recurrent urinary tract infection.
CONCLUSION: Hyperparathyroidism during pregnancy, while rare, remains a preventable cause of fetal morbidity and mortality. Based on our case series and review of the literature, surgery is the definitive treatment of choice and is considered safe and effective if performed during the second trimester of pregnancy. Those involved with the care of the pregnant patient need to be diligent to diagnose and treat this entity promptly.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10037311     DOI: 10.1016/s0002-9610(98)00302-x

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  28 in total

Review 1.  Thyroid and parathyroid surgery in pregnancy.

Authors:  Randall P Owen; Katherine J Chou; Carl E Silver; Yaakov Beilin; Jian J Tang; Robert T Yanagisawa; Alessandra Rinaldo; Ashok R Shaha; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-09-28       Impact factor: 2.503

2.  Primary Hyperparathyroidism in Pregnancy: A Multicenter Case Series of 4 Patients from Northern India.

Authors:  Ajay Aggarwal; Roopak Wadhwa; Vivek Aggarwal; Arun Pande; Swadesh Kumar Singh; Ankur Gahlot; Deependra Narayan Singh; Abhinav Sharma
Journal:  J Obstet Gynaecol India       Date:  2018-07-05

3.  Definition and Multiple Factors of Recurrent Spontaneous Abortion.

Authors:  Xiaolin La; Wenjuan Wang; Meng Zhang; Li Liang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Hyperparathyroidism in pregnancy: options for localization and surgical therapy.

Authors:  Todd P W McMullen; Diana L Learoyd; David C Williams; Mark S Sywak; Stan B Sidhu; Leigh W Delbridge
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

5.  Hyperparathyroidism during Pregnancy- A Diagnostic and Therapeutic Challenge.

Authors:  Richa Sharma; Vishnu Bhartiya; Kiran Guleria; Amita Suneja
Journal:  J Clin Diagn Res       Date:  2017-09-01

6.  Three case reports of maternal primary hyperparathyroidism in each trimester and a review of optimal management in pregnancy.

Authors:  Elaine Hui; Osaeloke Osakwe; Tiong Ghee Teoh; Neil Tolley; Stephen Robinson
Journal:  Obstet Med       Date:  2010-03-04

7.  Treatment approach for primary hyperparathyroidism in pregnancy.

Authors:  Azka Latif; Alheli Arce Gastelum; Kinaan Farhan; Sunil Jagadesh; Sangeeta Mutnuri
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-10-28

8.  Primary hyperparathyroidism mimicking hyperemesis gravidarum.

Authors:  Brian C Benson; Roy E Guinto; Jonathan R Parks
Journal:  Hawaii J Med Public Health       Date:  2013-01

9.  Two cases of primary hyperparathyroidism in pregnancy.

Authors:  Paul Hession; Jennifer Walsh; Geraldine Gaffney
Journal:  BMJ Case Rep       Date:  2014-01-27

Review 10.  Primary hyperparathyroidism in pregnancy.

Authors:  Gonzalo Diaz-Soto; Agnès Linglart; Marie-Victoire Sénat; Peter Kamenicky; Philippe Chanson
Journal:  Endocrine       Date:  2013-05-14       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.